| In millions, except per share items | Jun-30-07 | Jun-30-06 | Jun-30-05 | Jun-30-04 | Jun-30-03 | Jun-30-02 | Jun-30-01 | Jun-30-00 |
| | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K/A | 10-K |
| Revenues: |
| Dental segment | 48.1 | 42.9 | 37.2 | | | | | |
| Oral restorative products | | | | 31.7 | 26.8 | | 20.0 | 20.1 |
| Hyaluronan segment | 21.6 | 20.2 | 18.5 | | | | | |
| Hyaluronan products | | | | 15.7 | 15.7 | | 14.2 | 12.8 |
| Total revenues | 69.6 | 63.1 | 55.7 | 47.4 | 42.4 | 38.8 | 34.1 | 32.8 |
| Revenue growth [+] | 10.4% | 13.3% | 17.4% | 11.7% | 9.4% | 13.6% | 4.0% | 20.1% |
| Dental segment | 11.9% | 15.5% | | | | | | |
| Oral restorative products | | | | 18.3% | | | -0.5% | 4.8% |
| Hyaluronan segment | 7.0% | 8.8% | | | | | | |
| Hyaluronan products | | | | 0.5% | | | 11.1% | 55.9% |
| Cost of goods sold | 26.0 | 23.9 | 22.4 | 20.9 | 20.4 | 22.1 | 18.5 | 17.6 |
| Gross profit | 43.6 | 39.2 | 33.3 | 26.6 | 22.1 | 16.7 | 15.6 | 15.2 |
| Gross margin | 62.6% | 62.1% | 59.8% | 56.0% | 52.0% | 43.0% | 45.8% | 46.3% |
| Selling, general and administrative [+] | 27.8 | 24.5 | 21.0 | 20.2 | 17.9 | 15.8 | 13.9 | 11.8 |
| Sales and marketing | 20.3 | 17.5 | 14.9 | 13.8 | 12.4 | 10.8 | 9.3 | 7.9 |
| General and administrative | 7.6 | 7.1 | 6.2 | 6.4 | 5.5 | 5.0 | 4.6 | 3.8 |
| Research and development | 4.6 | 3.8 | 4.2 | 4.5 | 4.1 | 4.9 | 4.7 | 4.2 |
| EBITDA [+] | 13.4 | 12.9 | 10.2 | 4.4 | 3.0 | -1.1 | 0.3 | 2.5 |
| EBITDA growth | 3.8% | 27.2% | 130.8% | 48.0% | -381.5% | -416.2% | -86.8% | -53.0% |
| EBITDA margin | 19.3% | 20.5% | 18.2% | 9.3% | 7.0% | -2.7% | 1.0% | 7.7% |
| Depreciation and amortization | 2.3 | 2.0 | 2.1 | 2.5 | 2.9 | 2.9 | 3.3 | 3.3 |
| EBIT [+] | 11.2 | 10.9 | 8.1 | 1.9 | 0.1 | -4.0 | -3.0 | -0.8 |
| EBIT growth | 2.5% | 34.8% | 329.3% | 1799.0% | -102.5% | 34.5% | 290.0% | -133.2% |
| EBIT margin | 16.0% | 17.2% | 14.5% | 4.0% | 0.2% | -10.3% | -8.7% | -2.3% |
| Non-recurring items | | | | 1.1 | | | | |
| Interest expense, net [+] | -1.2 | -0.5 | 0.1 | 0.6 | 0.7 | 0.7 | 0.6 | 0.8 |
| Interest expense | 0.3 | 0.3 | 0.3 | 0.6 | 0.8 | 0.7 | 0.8 | 0.9 |
| Interest income | 1.5 | 0.8 | 0.2 | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 |
| Other income (expense), net | 0.2 | 0.0 | 0.4 | 0.7 | 0.3 | 0.0 | -0.1 | 0.0 |
| Pre-tax income | 12.6 | 11.4 | 8.4 | 0.9 | -0.3 | -4.7 | -3.7 | -1.6 |
| Income taxes | 4.9 | 4.4 | -9.1 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 38.6% | 38.4% | | 19.1% | | | 0.0% | 0.0% |
| Net income | 7.7 | 7.0 | 17.5 | 0.7 | -0.4 | -4.7 | -3.7 | -1.6 |
| Net margin | 11.1% | 11.2% | 31.4% | 1.5% | -0.8% | -12.2% | -10.8% | -4.9% |
| |
| Basic EPS [+] | $0.58 | $0.54 | $1.35 | $0.05 | ($0.03) | ($0.37) | ($0.29) | |
| Growth | 8.2% | -60.3% | 2362.1% | -298.9% | -92.5% | 25.7% | | |
| Diluted EPS [+] | $0.56 | $0.52 | $1.31 | $0.05 | ($0.03) | ($0.37) | ($0.29) | |
| Growth | 7.9% | -60.4% | 2305.0% | -298.0% | -92.5% | 25.7% | | |
| |
| Shares outstanding (basic) [+] | 13.3 | 13.1 | 13.0 | 12.9 | 12.9 | 12.8 | 12.6 | |
| Growth | 1.3% | 1.3% | 0.6% | 0.1% | 0.6% | 1.4% | | |
| Shares outstanding (diluted) [+] | 13.8 | 13.6 | 13.3 | 13.0 | 12.9 | 12.8 | 12.6 | |
| Growth | 1.6% | 1.6% | 3.0% | 0.6% | 0.6% | 1.4% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |